risedronic acid has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High lung deposition and bioavailability of RIS was monitored with 88." | 1.72 | Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. ( Cao, J; Chen, H; Chen, R; Liu, D; Su, B; Tang, Y; Wu, D; Xu, J; Xu, W, 2022) |
| "We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111)." | 1.51 | Predictive and modifying factors of bone mineral density decline in patients with COPD. ( Asano, K; Betsuyaku, T; Chubachi, S; Fukunaga, K; Irie, H; Kameyama, N; Nakamura, H; Sakurai, K; Sasaki, M; Sayama, K; Tsutsumi, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, D | 1 |
| Xu, W | 1 |
| Tang, Y | 1 |
| Cao, J | 1 |
| Chen, R | 1 |
| Wu, D | 1 |
| Chen, H | 1 |
| Su, B | 1 |
| Xu, J | 1 |
| Kameyama, N | 1 |
| Chubachi, S | 1 |
| Sasaki, M | 1 |
| Tsutsumi, A | 1 |
| Irie, H | 1 |
| Sakurai, K | 1 |
| Sayama, K | 1 |
| Nakamura, H | 1 |
| Asano, K | 1 |
| Betsuyaku, T | 1 |
| Fukunaga, K | 1 |
2 other studies available for risedronic acid and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling.
Topics: Airway Obstruction; Animals; Inflammation; Lung; Mice; NF-kappa B; Prenylation; Pulmonary Disease, C | 2022 |
Predictive and modifying factors of bone mineral density decline in patients with COPD.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Female; Humans | 2019 |